Bristol-Myers opens up the Phase 0 pathway in testing its new cancer therapies, following in Celgene’s footsteps

So it’s particularly interesting to see Bristol-Myers tie-up with Seattle-based Presage Biosciences on Phase O testing, which will use microdoses of multiple drugs and combos on patients to gauge their pharmacodynamic effects. That way researchers can help determine if they’re on the right track as they lay out plans to develop drugs in much more extensive studies.